Botanical/Drug Interaction Studies Should Be Based On Safety Risk - CHPA

"Extensive" investigation of drug-drug interactions for botanical drug products is not necessary unless a safety risk is indicated by adverse event reports or other animal or clinical data, the Consumer Healthcare Products Association asserts.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet